Coronary vasospasm with myocardial stunning in a patient with colon cancer receiving adjuvant chemotherapy with FOLFOX regimen

Clinical Colorectal Cancer

Volumn 8, Issue 1, 2009, Pages 55-58

  Cerny, Jan ^a   Hassan, Amr ^a   Smith, Craig ^b   Piperdi, Bilal ^a,b  

^a Division of Hematology and Oncology   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Adjuvant chemotherapy; Bolus 5 fluorouracil; Cardiac toxicity; Infusion; MFOLFOX6

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CAPECITABINE; CARBOPLATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; NITRATE; OXALIPLATIN; VERAPAMIL;

ADJUVANT THERAPY; ADULT; ARTICLE; BOLUS INJECTION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CASE REPORT; CLINICAL PRACTICE; COLON CANCER; CORONARY ARTERY SPASM; DRUG MEGADOSE; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY MONITORING; HEART EJECTION FRACTION; HEART VENTRICULOGRAPHY; HUMAN; LOW DRUG DOSE; MALE; PATIENT MONITORING; PRACTICE GUIDELINE; STUNNED HEART MUSCLE; TREATMENT OUTCOME;

EID: 61349139283     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2009.n.009     Document Type: Article

References (25)

1. Kubler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007; 25:2198-204.
2. Becker K, Erckenbrecht JF, Háussinger D, et al. Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs 1999; 57:475-84.
3. De Forni M, Malet-Martino MC, Jaillais P, et al. Cardiotoxicity of high-dose continuous infusion florouracil: a prospective clinical study. J Clin Oncol 1992; 10:1795-801.
4. Schober C, Papageorgiou E, Harstrick A, et al. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer 1993; 72:2242-7.
5. Meydan N, Kundak I, Yavuzsen T, et al. Cardiotoxicity of de Gramont's regimen: incidence, clinical characteristics and long-term follow-up. Jpn J Clin Oncol 2005; 35:265-70.
6. Ng M, Cunningham D, Norman AR. The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). Eur J Cancer 2005; 41:1542-6.
7. Tsibiribi P, Descotes J, Lombard-Bohas C, et al. Cardiotoxicity of 5-fluorouracil in 1350 patients with no prior history of heart disease. Bull Cancer 2006; 93:E27-30.
8. Jensen SA, Sorensen JB. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 2006; 58:487-93.
9. Kosmas C, Kallistratos MS, Kopterides P, et al. Cardiotoxicity of fluoropyrimi-dines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 2008; 134:75-82.
10. Kosmas C, Kallistratos MS, Kopterides P, et al. Cardiotoxicity of fluoropyrimi-dines in diferent schedules of administration: a prospective study. J Cancer Res Clin Oncol 2008; 134:75-82.
11. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34:1274-81.
12. Gradishar W, Vokes E, Schilsky R, et al. Vascular events in patients receiving high-dose infusional 5-fluorouracil-based chemotherapy: the University of Chicago experience. Med Pediatr Oncol 1991; 19:8-15.
13. Rezkalla S, Kloner RA, Ensley J, et al. Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. J Clin Oncol 1989; 7:509-14.
14. Burger W, Chemnitius JM, Metz MZ, et al. A model for the study of coronary spasm induced changes in cardiac metabolism. J Mol Cell Cardiol 1985; 17:917-30.
15. Kuzel T, Esparaz B, Green D, et al. Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. Cancer 1990; 65:885-9.
16. Shoemaker LK, Arora U, Rocha Lima CM. 5-Fluorouracil-induced coronary vasospasm. Cancer Control 2004; 11:46-9.
17. Sudhoff T, Enderle MD, Pahlke M, et al. 5-Fluorouracil induces arterial vasocon-tractions. Ann Oncol 2004; 15:661-4.
18. Porta C, Moroni M, Ferrari S, et al. Endothelin-1 and 5-fluorouracil induced cardiotoxicity. Neoplasma 1998; 45:81-2.
19. McDermott BJ, van den Berg HW, Murphy RF. Nonlinear pharmacokinetics for the elimination of 5-fluorouracil after intravenous administration in cancer patients. Cancer Chemother Pharmacol 1982; 9:173-8.
20. Muneoka K, Shirai Y, Yokoyama N, et al. 5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine. Int J Clin Oncol 2005; 10:441-3.
21. Patel B, Kloner RA, Ensley J et al. 5-Fluorouracil cardiotoxicity: left ventricular dysfunction and effect of coronary vasodilators. Am J Med Sci 1987; 294:238-43.
22. Eskilsson J, Albertsson M. Failure of preventing 5-fluorouracil cardiotoxicity by prophylactic treatment with verapamil. Acta Oncol 1990; 8:1001-3.
23. Oleksowicz L, Bruckner HW. Prophylaxis of 5-fluorouracil induced coronary vasospasm with calcium channel blockers. Am J Med 1988; 85:750-1.
24. Norbertus CR, Pippas AW, Moore JO. The syndrome of 5-fluorouracil cardiotox-icity: an elusive cardiopathy. Cancer 1993; 71:493-509.
25. Alter P, Herzum M, Soufi M, et al. Cardiotoxicity of 5-fluorouracil. Cardiovasc Hematol Agents Med Chem 2006; 4:1-5.